Clinical trials: Systemic Disease
Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic
A Non-drug Study Profiling Cutaneous Lupus
The purpose of this study is to characterize the clinical and molecular profiles of patients with cutaneous lupus.
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
- Trial name
- NCT01923415
- Testing
- No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
- Where
- 3 sites in United States, Poland
- Volunteers
- 29 people
- Sponsor
- Janssen Research & Development, LLC
Systemic Sclerosis
A Clinical Study to Test How Effective and Safe GLPG1690 is for Participants With Systemic Sclerosis
The main purpose of the study is to see if GLPG1690 helps (together with the standard of care treatment) in the treatment of the skin and other areas affected by systemic sclerosis.
- Trial name
- NOVESA (NCT03798366)
- Testing
- GLPG1690
- Where
- 18 sites in United States, Belgium and 4 more
- Volunteers
- 33 people
- Sponsor
- Lakefront Biotherapeutics NV
Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE)
The primary purpose of this study is to evaluate the efficacy, safety, and tolerability of IMVT-1402 in participants with Cutaneous Lupus Erythematosus.
- Trial name
- NCT06980805
- Testing
- IMVT-1402
- Where
- 86 sites in United States, Argentina and 11 more
- Volunteers
- 56 people
- Sponsor
- Immunovant Sciences GmbH
Melanoma
A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy
The purpose of this study is to examine real-world data among participants with stage IIIa melanoma initiating nivolumab as adjuvant treatment in the community practice setting by utilizing patient data from the United States…
- Trial name
- NCT05432622
- Where
- United States
- Volunteers
- 95 people
- Sponsor
- Bristol-Myers Squibb
Systemic Lupus Erythematosus
An Adaptive Phase II Study to Evaluate the Efficacy, Pharmacodynamics, Safety and Tolerability of GSK2586184
This is an adaptive, dose ranging, Phase II study to investigate the relationship between repeat doses of GSK2586184 and the pharmacodynamic effect and clinical efficacy in patients with active systemic lupus erythematosus (SLE).
- Trial name
- NCT01777256
- Testing
- GSK2586184 50 mg, GSK2586184 100 mg, GSK2586184 200 mg
- Where
- 53 sites in Argentina, Chile and 14 more
- Volunteers
- 51 people
- Sponsor
- GlaxoSmithKline
Scleroderma, Systemic
Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
To investigate if Riociguat is effective in the treatment of systemic sclerosis
- Trial name
- NCT02283762
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 59 sites in United States, Australia and 13 more
- Volunteers
- 121 people
- Sponsor
- Bayer
Lupus Nephritis
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
The primary objective of this study is to evaluate the efficacy of zanubrutinib added to standard of care as measured by complete renal response for participants with active proliferative lupus nephritis
- Trial name
- NCT04643470
- Testing
- Zanubrutinib
- Where
- 44 sites in China
- Volunteers
- 177 people
- Sponsor
- BeiGene
Systemic Lupus Erythematosus (SLE)
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
This was a multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical study. The primary objective was to evaluate the efficacy of SG301 SC injection in participants with Systemic Lupus Erythematosus (SLE) based…
- Trial name
- NCT07447986
- Testing
- SG301 SC Injection
- Where
- 40 sites in China
- Volunteers
- 120 people
- Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
Systemic Lupus Erythematosus
Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis
The purpose of this study is to determine the safety and tolerability of Anti-MIF Antibody in subjects with lupus nephritis.
- Trial name
- NCT01541670
- Testing
- Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody
- Where
- 24 sites in United States, Australia and 3 more
- Volunteers
- 4 people
- Sponsor
- Baxalta now part of Shire
Lung Diseases, Obstructive, Sarcoidosis
Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD")
The purpose of this study is to evaluate the safety, effectiveness, and side effects of the CryoSpray AblationTM System (CryoSpray AblationTM, "CSA" or "cryospray therapy") to treat benign airway disease in the lung using liquid…
- Conditions
- Lung Diseases, Obstructive, Sarcoidosis, Wegener's Granulomatosis, Rhinoscleroma
- Trial name
- ICEtheBAD (NCT00747461)
- Testing
- CryoSpray Ablation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- CSA Medical, Inc.
Advanced Gastric Cancer
Safety and Efficacy of RAD001 (Everolimus) Monotherapy Plus Best Supportive Care in Patients With Advanced Gastric Cancer (AGC)
This study is designed to assess the safety and efficacy of RAD001 monotherapy in patients with advanced gastric cancer which has progressed after one or two lines of prior chemotherapy.
- Trial name
- GRANITE-1 (NCT00879333)
- Testing
- Everolimus, Best Supportive Care (BSC)
- Where
- 122 sites in United States, Argentina and 20 more
- Volunteers
- 656 people
- Sponsor
- Novartis Pharmaceuticals
Systemic Lupus Erythematosus
Exploratory Study of MT-1303 in Systemic Lupus Erythematosus Patients
The purpose of this study is to evaluate the safety/tolerability and to explore the efficacy of MT-1303 in subjects with systemic lupus erythematosus
- Trial name
- NCT02307643
- Testing
- MT-1303 Low dose, MT-1303 High dose
- Where
- 14 sites in Japan
- Volunteers
- 17 people
- Sponsor
- Tanabe Pharma Corporation
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
The purpose of this study is to make a preliminary assessment of the efficacy of a combined APR-246 and carboplatin/PLD chemotherapy regimen, compared with carboplatin/PLD chemotherapy regimen alone, in patients with platinum…
- Trial name
- NCT02098343
- Testing
- APR-246, Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)
- Where
- 55 sites in United States, Belgium and 6 more
- Volunteers
- 247 people
- Sponsor
- Aprea Therapeutics
Lupus Nephritis
LUPKYNIS Drug-use Results Survey
The purpose of this study is to survey the safety of LUPKYNIS in patients with lupus nephritis under actual use conditions. In addition, information on efficacy will be collected.
- Trial name
- NCT07053891
- Testing
- Voclosporin (LUPKYNIS)
- Where
- Japan
- Volunteers
- 400 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Moderate to Severe Chronic Plaque-type Psoriasis
Study to Assess the Long-term Safety, Tolerability, Efficacy of Secukinumab in Pediatric Patients of Age 6 to <18 Years, With Moderate to Severe Plaque Psoriasis
This was an open-label, parallel-group, two-arm, multicenter study in pediatric subjects aged 6 years to less than 18 years, at randomization, with moderate to severe chronic plaque psoriasis.
- Trial name
- NCT03668613
- Testing
- secukinumab low dose, secukinumab high dose
- Where
- 23 sites in United States, Belgium and 7 more
- Volunteers
- 84 people
- Sponsor
- Novartis Pharmaceuticals
Acute Pancreatitis, Systemic Inflammatory Response Syndrome
CM4620 Injectable Emulsion Versus Supportive Care in Patients With Acute Pancreatitis and SIRS
This open-label, dose-response study will evaluate the safety and efficacy of CM4620-IE in patients with acute pancreatitis and accompanying SIRS. The study will consist of two phases.
- Trial name
- NCT03401190
- Testing
- CM4620 Injectable Emulsion (Low Dose), CM4620 Injectable Emulsion (High Dose)
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- CalciMedica, Inc.
Systemic Lupus Erythematosus, Rheumatoid Arthritis
A Phase I Study of ICP-022 in Healthy Subjects
This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and…
- Trial name
- NCT03189017
- Testing
- ICP-022
- Where
- Australia
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Innocare Pharma Australia Pty Ltd
Systemic Lupus Erythematosus (SLE)
A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SCTC21C in participants with systemic lupus erythematosus
- Trial name
- NCT07538154
- Testing
- SCTC21C
- Volunteers
- 159 people
- Sponsor
- Sinocelltech Ltd.
Sclerosis, Systemic
A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis
This multicenter, randomized, double-blind, placebo-controlled, two-arm, parallel-group study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in participants with systemic sclerosis.
- Trial name
- NCT01532869
- Testing
- tocilizumab [RoActemra/Actemra]
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 87 people
- Sponsor
- Hoffmann-La Roche
Lupus Erythematosus, Systemic
Achievement of LLDAS5 in Patients With Systemic Lupus Erythematosus Treated With Anifrolumab.
This is an observational, multicenter, prospective study on patients with systemic lupus erythematosus treated with anifrolumab in Italy aimed at evaluating the achievement of LLDAS5
- Trial name
- DAHLIA (NCT07330245)
- Testing
- Anifrolumab
- Where
- 22 sites in Italy
- Volunteers
- 218 people
- Sponsor
- AstraZeneca